Statin treatment alters serum n-3 to n-6 polyunsaturated fatty acids ratio in patients with dyslipidemia by unknown
Nozue and Michishita Lipids in Health and Disease  (2015) 14:67 
DOI 10.1186/s12944-015-0066-6SHORT REPORT Open AccessStatin treatment alters serum n-3 to n-6
polyunsaturated fatty acids ratio in patients
with dyslipidemia
Tsuyoshi Nozue* and Ichiro MichishitaAbstract
Background: The effects of statins on serum n-3 to n-6 polyunsaturated fatty acids (PUFAs) levels have not been
fully evaluated. We examined the effects of two types of statins (rosuvastatin and pitavastatin) on serum PUFAs
levels and their ratios in patients with dyslipidemia.
Findings: A total of 46 patients who were not receiving lipid-lowering therapy were randomly assigned to receive
either 2.5 mg/day of rosuvastatin or 2 mg/day of pitavastatin. Serum PUFAs levels were measured at baseline, at
4 weeks, and at 12 weeks. Rosuvastatin was used to treat 23 patients, and the remaining 23 patients were treated
using pitavastatin. Serum docosahexaenoic acid (DHA) levels decreased significantly at 12 weeks in both groups
(rosuvastatin: from 169.6 to 136.3 μg/mL, p = 0.006; pitavastatin: from 188.6 to 153.9 μg/mL, p = 0.03). However,
serum levels of eicosapentaenoic acid (EPA) and arachidonic acid (AA) did not change. In addition, the EPA/AA ratio
did not change, whereas the DHA/AA ratio decreased significantly at 12 weeks in both groups (rosuvastatin: from
0.99 to 0.80, p = 0.01; pitavastatin: from 1.14 to 0.91, p = 0.003). No adverse events were observed during the study
period.
Conclusions: In this small, open-label, pilot study, rosuvastatin and pitavastatin decreased serum DHA levels and
the DHA/AA ratio in patients with dyslipidemia.
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Numerous clinical trials have shown that statins can
significantly reduce the incidence of cardiovascular dis-
ease. Furthermore, intensive lipid-lowering therapy with
statins yields a significantly greater reduction in the risk
of coronary events compared to moderate lipid-lowering
therapy [1, 2]. Nonetheless, a residual risk is present in
all of the statin trials [3]. Statins and polyunsaturated
fatty acids (PUFAs) have similar actions such as enhance
endothelial nitric synthesis, inhibit the production of
pro-inflammatory cytokines, and prevent atherosclerosis
[4]. Thus, the residual risk of cardiovascular events after
statin therapy is explained in part by the n-3 to n-6 poly-
unsaturated fatty acids (PUFAs) ratios [5].* Correspondence: nozue2493@yahoo.co.jp
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creativecommons.org/publicdomain/zero/1.0/The effects of statins on serum n-3 to n-6 PUFAs
levels and these ratios have not been fully evaluated. Re-
cently, we reported that pitavastatin decreased serum
docosahexaenoic acid (DHA)/arachidonic acid (AA) ra-
tio, whereas pravastatin had no effect on this ratio [6].
However, Nakamura et al. reported that pravastatin and
simvastatin decreased serum eicosapentaenoic acid
(EPA)/AA ratio [7]. Harris et al. also reported that serum
EPA/AA ratio was decreased by simvastatin [8]. Based on
these reports, we hypothesized that the effects of statin on
n-3 to n-6 PUFAs ratios would be depend on types of sta-
tin. To test this hypothesis, we examined the effects of two
types of statins (rosuvastatin and pitavastatin) on serum
PUFAs levels and their ratios in patients with dyslipidemia.
Methods
Patients and study design
Between June 2009 and May 2011, outpatients with
dyslipidemia who were being treated at our hospitalAccess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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target lipid levels recommended by the Japan Athero-
sclerosis Society Guidelines [9] despite diet and exercise
for 3 months. The following patients were excluded from
the study: (1) those treated with lipid-lowering drugs (sta-
tins, PUFAs, fibrates, nicotinic acid, colestyramine, or pro-
bucol), (2) those with dyslipidemia associated with
hypothyroidism, nephrotic syndrome, gallbladder obstruc-
tion, biliary disease, pancreatitis, or immunologic abnormal-
ities such as collagen diseases, (3) those with dyslipidemia
induced by steroids or other drugs, (4) those with severe
liver dysfunction, (5) alcoholism or heavy alcohol intake, (6)
any other reason for which the patient was considered
inappropriate for this study by the attending physician.
A total of 46 patients were randomly assigned to
receive either 2.5 mg/day of rosuvastatin or 2 mg/day of
pitavastatin. Serum PUFAs levels were measured at base-
line, at 4 weeks, and at 12 weeks. Adverse effects were
assessed at each study visit by patient interviews and
laboratory testing. During the study period, there were
no lifestyle changes, the use of non-study anti-dyslipid-
emic agents was prohibited, and anti-hypertensive and
anti-diabetic therapy used at enrollment was continued
without dosage modifications.
There are 2 distinct classes of statins: lipophilic (pitavas-
tatin, atorvastatin, fluvastatin, and simvastatin) and hydro-
philic (pravastatin and rosuvastatin) [10]. Pitavastatin is a
commonly used lipophilic strong statin in Japan, and its
ability to lower serum low-density lipoprotein cholesterol
(LDL-C) is comparable with that of atorvastatin [11].
Rosuvastatin was selected as hydrophilic strong statin.
This study was conducted in accordance with the
Declaration of Helsinki and with the approval of the
ethical committees of Yokohama Sakae Kyosai Hospital.
Written informed consent was obtained from each
patient enrolled in the study.Table 1 Baseline characteristics of subjects
Rosuvastatin (n = 23) Pitavastatin (n = 23) p value
Age (years) 69 (48-86) 66 (47-83) 0.31
Male gender, n 12/23 14/23 0.55
Height (cm) 163 (145-173) 163 (147-180) 0.8
Body weight (kg) 63 (44-88) 65 (38-80) 0.35
BMI (kg/m2) 23.5 (17.6-32.6) 24.0 (17.3-28.7) 0.5
Smoking, n 2/23 2/23 >0.99
History of CAD, n 5/23 4/23 >0.99
Diabetes mellitus, n 9/23 11/23 0.55
Hypertension, n 14/23 9/23 0.14
Data are expressed as median (range) or number
BMI, body mass index; CAD, coronary artery diseaseLaboratory determinations
Blood samples were obtained after an overnight fast at
baseline, at 4 weeks, and at 12 weeks. Serum levels of
total cholesterol, LDL-C, high-density lipoprotein chol-
esterol (HDL-C), and triglycerides (TG) were measured
by standard enzymatic methods on AU2700 (Beckman
Coulter, CA, USA) using commercial enzymatic kits
(Kyowa Medex, Tokyo, Japan). Serum apolipoprotein
A1, B, and E levels were measured by turbidimetric
immunoassay at a central laboratory (SRL Inc., Tokyo,
Japan). Serum levels of four bioactive fatty acids, including
EPA, DHA, AA, and dihomogamma-linolenic acid, were
measured using a gas chromatograph (GC-2010;
Shimadzu Corporation, Kyoto, Japan) equipped with a
capillary column (TC-70; GL Sciences, Tokyo, Japan) at a
central laboratory (SRL Inc., Tokyo, Japan).Statistical analysis
Statistical analyses were performed using StatView ver-
sion 5.0 (SAS Institute, Cary, North Carolina, USA). The
results were expressed as median (range). The Wilcoxon
signed rank test was used to compare the data before
and after statin therapy. Categorical variables between
the 2 groups were compared using the chi-square test or
the Fisher’s exact test. The statistical significance level
was set at p < 0.05. Corrections for multiple comparisons
and a sample-size calculation were not performed.Findings
Twenty-three patients were assigned to rosuvastatin
group, and the remaining 23 patients to pitavastatin
group. The baseline characteristics of subjects are shown
in Table 1. The baseline characteristics did not differ
between the 2 groups. The number of diabetes mellitus
was 9 in rosuvastatin group and 11 in pitavastatin group.
Five patients in rosuvastatin group and 4 patients in
pitavastatin group had a prior history of coronary artery
disease.
The effects of statins on lipid levels are shown in
Table 2. Serum levels of total cholesterol, LDL-C, TG,
apolipoprotein B and E decreased significantly in both
groups. However, significant increases in HDL-C and
apolipoprotein A1 levels were observed only in rosuvas-
tatin group.
Serum PUFAs levels and their ratios at baseline, at
4 weeks, and at 12 weeks are shown in Table 3. Serum
levels of EPA and AA did not change, whereas the DHA
levels decreased significantly at 12 weeks in both groups
(rosuvastatin: from 169.6 to 136.3 μg/mL, p = 0.006;
pitavastatin: from 188.6 to 153.9 μg/mL, p = 0.03). As a
result, a significant decrease in the DHA/AA ratio was
observed (rosuvastatin: from 0.99 to 0.80, p = 0.01;
pitavastatin: from 1.14 to 0.91, p = 0.003), whereas the
EPA/AA ratio showed no significant change in both
groups. No adverse events, including the occurrence of
Table 2 Effects of rosuvastatin and pitavastatin on serum lipid levels
Baseline 4 weeks p value 12 weeks p value
TC (mg/dL) Rosuvastatin 232 (160-288) 163 (126-209) <0.0001 171 (125-206) <0.0001
Pitavastatin 249 (174-301) 178 (111-215) <0.0001 183 (118-252) <0.0001
LDL-C (mg/dL) Rosuvastatin 159 (103-216) 83 (55-145) <0.0001 88 (50-138) <0.0001
Pitavastatin 176 (117-240) 106 (46-155) <0.0001 98 (48-180) <0.0001
HDL-C (mg/dL) Rosuvastatin 56 (36-79) 61 (40-90) 0.07 63 (38-103) 0.005
Pitavastatin 60 (41-93) 62 (41-125) 0.14 63 (40-120) 0.16
TG (mg/dL) Rosuvastatin 164 (75-396) 116 (70-211) 0.002 110 (71-312) 0.009
Pitavastatin 169 (84-303) 134 (61-316) 0.01 121 (64-311) 0.01
Apo Al (mg/dL) Rosuvastatin 144 (106-172) 151 (116-192) 0.01 147 (116-234) 0.004
Pitavastatin 150 (119-203) 149 (100-256) 0.35 152 (94-257) 0.19
Apo B (mg/dL) Rosuvastatin 116 (76-159) 75 (52-106) <0.0001 77 (49-103) <0.0001
Pitavastatin 132 (86-176) 87 (43-111) <0.0001 88 (43-143) <0.0001
Apo E (mg/dL) Rosuvastatin 4.7 (3.6-7.6) 3.7 (2.6-5.2) <0.0001 3.6 (2.4-4.6) <0.0001
Pitavastatin 5.4 (3.3-11.9) 4.3 (2.2-8.0) <0.0001 4.3 (2.7-9.7) <0.0001
Data are expressed as median (range)
TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, trigycerides; Apo, apolipoprotein
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eters, were observed during the study period.
Discussion
The major findings of the present study are as follows:
(1) rosuvastatin and pitavastatin decreased serum DHA
levels and a significant decrease in the DHA/AA ratio
was observed, and (2) the EPA/AA ratio showed no sig-
nificant change in both statins.
Few studies have reported the effects of statins on n-3
to n-6 PUFA ratios. One study reported that pravastatin
and simvastatin increased the AA level significantlyTable 3 Effects of rosuvastatin and pitavastatin on serum PUFAs lev
Baseline 4 we
EPA (μg/mL) Rosuvastatin 66.9 (28.9-199.9) 70.
Pitavastatin 87.0 (15.2-149.8) 65.
DHA (μg/mL) Rosuvastatin 169.6 (98.1-384-6) 142.
Pitavastatin 188.6 (91.8-283.6) 135.
DGLA (μg/mL) Rosuvastatin 36.2 (18.1-74.4) 34.
Pitavastatin 37.4 (18.4-57.3) 35.
AA (μg/mL) Rosuvastatin 168.3 (114.6-284.9) 158.
Pitavastatin 167.3 (106.0-279.2) 166.
EPA/AA Rosuvastatin 0.42 (0.13-1.65) 0.4
Pitavastatin 0.51 (0.07-1.19) 0.3
DHA/AA Rosuvastatin 0.99 (0.42-1.82) 0.8
Pitavastatin 1.14 (0.08-1.18) 0.8
EPA + DHA/AA Rosuvastatin 1.42 (0.55-3.34) 1.2
Pitavastatin 1.75 (0.52-2.85) 1.2
Data are expressed as median (range)
PUFAs, polyunsaturated fatty acids; EPA, eicosapentaenoic acid; DHA, docosahexaenwhereas they did not affect EPA and DHA levels, result-
ing in a significant decrease in the EPA/AA ratio [7].
The other study reported that concentration of AA were
unchanged while the EPA/AA ratio was decreased
significantly by simvastatin [8]. On the other hand,
rosuvastatin, pitavastatin, and atorvastatin mainly re-
duced n-3 PUFAs [12]. According to these previous re-
ports, the effects of statins on serum PUFAs levels have
varied. However, we reported recently that pitavastatain
decreased the DHA/AA ratio, whereas pravastatin had no
effect on this ratio [6]. Thus, considering of the results of
this study, it seems that strong statins (e.g., rosuvastatin,els and their ratios
eks p value 12 weeks p value
2 (31.5-156.7) 0.69 64. 8 (23.7-216.9) 0.83
6 (16.0-201.5) 0.06 79.8 (17.8-205.0) 0.51
5 (66.0-215.6) 0.005 136.3 (56.0-251.9) 0.006
2 (80.3-198.8) 0.0004 153.9 (93.8-250.4) 0.03
2 (18.3-53.3) 0.06 33.6 (17.1-56.5) 0.18
4 (20.0-53.5) 0.13 36.7 (23.5-58.9) 0.48
3 (104.2-276.7) 0.43 163.2 (88.9-269.2) 0.81
0 (102.0-242.6) 0.89 180.2 (97.0-236.9) 0.2
4 (0.13-1.45) 0.36 0.37 (0.10-1.48) 0.91
8 (0.07-1.27) 0.14 0.43 (0.08-1.18) 0.25
1 (0.37-1.69) 0.05 0.80 (0.35-1.76) 0.01
7 (0.37-1.77) 0.0002 0.91 (0.45-1.59) 0.003
5 (0.50-3.14) 0.54 1.25 (0.45-2.88) 0.07
2 (0.44-2.89) 0.002 1.34 (0.53-2.64) 0.03
oic acid; DGLA, dihomogamma-linolenic acid; AA, arachidonic acid
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and the DHA/AA ratio would be decreased by these types
of statin. On the other hand, first generation weak statins
(e.g., pravastatin, simvastatin) mainly decrease the EPA/
AA ratio.
The mechanisms of how statin treatment affects
serum PUFAs level have not been fully examined. Jula
et al. reported that simvastatin increases serum AA
levels due to an increase in Δ6- and Δ5-desaturase
enzyme activities [13]. Although the effects of other statins
on these enzyme activities have not been evaluated, statins
increase the formation of AA, EPA, and DHA by these
enzymes [14]. The AA, EPA, and DHA give rise to anti-in-
flammatory molecules such as lipoxins, resolvins, and
protectins [14]. Some of beneficial actions of statins are
explained by the formation of these anti-inflammatory
molecules [15]. Thus, PUFAs and their metabolites may
serve as second messengers of the actions of statins [4].
We speculate that the effects of statins on the formation
and conversion of PUFAs may be different among specific
types of statins.
In the JELIS trial, EPA added on statins (10 mg of
pravastatin or 5 mg of simvastatin) significantly
decreased the incidence of coronary events by 19 % [16].
Thus, combination of EPA with statins has been demon-
strated to reduce future cardiovascular events for pri-
mary and secondary prevention [17, 18]. Statins as well
as PUFAs can inhibit HMG-CoA reductase activity [19].
Inhibition of the mevalonate pathway by statins and
PUFAs prevents the function of small guanosine
triphosphatases and enhance the expression of bone
morphogenetic proteins [20]. In view of the similarity in
their actions, combination PUFAs with statins may
prove to be highly beneficial clinical effects. We consider
that DHA add on strong statins may be useful strategy
to prevent cardiovascular events, because strong statins
mainly decrease the DHA/AA ratio.
The present study had several limitations. First, this
was a small, open-label, pilot study and the observation
period was only 12 weeks. Second, we did not evaluate
total fatty acids. Third, lifestyle habits were not con-
trolled, and changes in the PUFAs composition of the
diet are reflected in the levels of serum PUFAs. In
addition, exercise or smoking may have affected the
present results. Therefore, a further, adequately powered,
randomized, controlled trial is necessary to confirm the
effect of different types of statin on n-3 to n-6 PUFAs
ratios.Conclusions
In this small, open-label, pilot study, rosuvastatin and
pitavastatin decreased serum DHA levels and the DHA/
AA ratio in patients with dyslipidemia.Abbreviations
AA: Arachidonic acid; DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic
acid; HDL-C: High-density lipoprotein cholesterol; JELIS: Japan EPA lipid
intervention study; LDL-C: Low-density lipoprotein cholesterol;
PUFAs: Polyunsaturated fatty acids; TG: Triglycerides.
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